 |
| Joint Pain Injections Market Growth |
The joint pain injections market is a rapidly growing segment of the orthopedic
therapeutics industry owing to the growing geriatric population and increasing
prevalence of joint disorders like osteoarthritis. Joint pain injections are
used to treat various types of joint and muscle pain. They involve direct
injection of medications like corticosteroids, hyaluronic acid or platelet-rich
plasma into the joints or surrounding tissues to relieve pain and inflammation.
Joint pain is a common problem faced by a large population worldwide due to
joint disorders, injuries or aging. Injections are frequently used to manage
joint pain as they provide fast and targeted relief from pain and swelling.
The global
joint pain injections market is estimated to be valued at US$ 9.46 Bn in 2024
and is expected to exhibit a CAGR of 8.7% over the forecast period 2024 to
2031.
Key Takeaways
Key players operating in the Joint
Pain Injections Market Growth
are Pfizer, Inc., Ferring Pharmaceuticals Inc., PACIRA BIOSCIENCES, Eli
Lilly and Company, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Sanofi,
Anika Therapeutics, Inc., Bioventus, Dr. Reddy’s Laboratories Ltd.,
Zimmer Biomet, Ferring B.V., SEIKAGAKU CORPORATION, and Ono Pharmaceutical Co.,
Ltd. The increasing geriatric population suffering from joint disorders like
osteoarthritis is driving the growth of key players in the market.
The rising prevalence of joint disorders due to sedentary lifestyles and
obesity has resulted in a growing demand for joint pain relief treatments.
According to studies, over 30 million Americans suffer from arthritis or joint
disorders. Non-invasive treatment options like injections are gaining
popularity over surgeries due to their convenience and effectiveness in
managing joint pain.
Technological advancements are expanding the product portfolio in the joint
pain injections market. New drug formulations that offer longer relief from
pain with minimal side effects are being introduced. Combination therapies
using platelet-rich plasma along with corticosteroids or hyaluronic acid are
proving more effective than single therapies for treating osteoarthritis.
Market Trends
Growing preference for biologics: With advances in biotechnology, novel
biologic joint pain therapies like platelet rich plasma and stem cell therapies
are emerging trends in pain management. Their natural compositions make them
safer alternatives to chemical drugs.
Personalized treatment approaches: With a better understanding of disease
pathology, tailored treatment plans are being designed using various injections
based on individual patient factors like severity and type of joint disorder.
This shift towards personalized care delivery is an important trend.
Market Opportunities
Emerging economies: Developing nations are expected to present lucrative
opportunities for market players due to rising healthcare investments,
increasing disease burden and growing medical tourism.
Combination therapies: Combining different classes of drugs and biologics can
achieve synergistic pain relief effects. Investment in clinical trials of
combination regimens holds promise.
Impact of COVID-19 on Joint Pain Injections Market Growth
The COVID-19 pandemic has impacted the growth of the joint pain injections
market. During the initial outbreak of the virus, there was a decline in the
number of surgeries and procedures performed which reduced the demand for joint
pain injections. Lockdowns and restrictions imposed by various governments made
it difficult for people to visit hospitals and clinics for treatment. With
healthcare resources diverted towards managing COVID-19 patients, elective
procedures were postponed which affected the market negatively. However, as
restrictions are being lifted gradually, the market is recovering. The demand
for pain management treatments is increasing again as people start focusing on
non-COVID healthcare needs. Manufacturers are restarting their production activities
to cater to the growing requirements. Teleconsultations have also emerged as an
alternative for patients to seek advice from doctors during this time. In the
coming years, as vaccination programmes lead to normalization, the joint pain
injections market is expected to regain its pre-COVID growth trajectory.
Players would need to ensure supply chain resilience and optimize production to
meet future demand spikes efficiently.
In terms of geographical regions, North America accounted for the largest share
of the joint pain injections market in terms of value owing to the rising
prevalence of osteoarthritis and musculoskeletal disorders. Availability of
advanced healthcare infrastructure and reimbursement policies have boosted
procedures related to joint injections in the US and Canada. Within Asia
Pacific, China currently holds the largest market for joint pain injections due
to growing medical tourism and increasing focus of players to tap the
opportunities in this region. With rising geriatric population and investments
in healthcare, China is expected to be the fastest growing regional market for
joint pain injections during the forecast period. Players would need to
establish local manufacturing and distribution networks to efficiently cater to
the Chinese market.
Get More Insights On This Topic: Joint
Pain Injections Market